Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Hypoxia-Inducible Factor 1
  • Kidney Neoplasms
  • Receptors, CXCR4
  • Transcription Factors
  • Von Hippel-Lindau Tumor Suppressor Protein

abstract

  • Inactivation of the von Hippel-Lindau tumor suppressor gene, VHL, is an archetypical tumor-initiating event in clear cell renal carcinoma (ccRCC) that leads to the activation of hypoxia-inducible transcription factors (HIFs). However, VHL mutation status in ccRCC is not correlated with clinical outcome. Here we show that during ccRCC progression, cancer cells exploit diverse epigenetic alterations to empower a branch of the VHL-HIF pathway for metastasis, and the strength of this activation is associated with poor clinical outcome. By analyzing metastatic subpopulations of VHL-deficient ccRCC cells, we discovered an epigenetically altered VHL-HIF response that is specific to metastatic ccRCC. Focusing on the two most prominent pro-metastatic VHL-HIF target genes, we show that loss of Polycomb repressive complex 2 (PRC2)-dependent histone H3 Lys27 trimethylation (H3K27me3) activates HIF-driven chemokine (C-X-C motif) receptor 4 (CXCR4) expression in support of chemotactic cell invasion, whereas loss of DNA methylation enables HIF-driven cytohesin 1 interacting protein (CYTIP) expression to protect cancer cells from death cytokine signals. Thus, metastasis in ccRCC is based on an epigenetically expanded output of the tumor-initiating pathway.

publication date

  • January 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3540187

Digital Object Identifier (DOI)

  • 10.1038/nm.3029

PubMed ID

  • 23223005

Additional Document Info

start page

  • 50

end page

  • 6

volume

  • 19

number

  • 1